Agios Pharmaceuticals (AGIO) Interest & Investment Income (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 12 years of Interest & Investment Income data on file, last reported at $8.3 million in Q2 2023.

• Quarterly Interest & Investment Income rose 360.35% year-over-year to $8.3 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $26.7 million (up 766.7% YoY) and the FY2022 annual result came in at $12.8 million, up 1430.26% from the prior year.
• Interest & Investment Income climbed to $8.3 million in Q2 2023, from $8.1 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $8.3 million in Q2 2023 to a low of -$973000.0 in Q3 2020.
• A 5-year average of $3.0 million and a median of $2.9 million in 2019 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2020 — Interest & Investment Income tumbled 133.7% — and 2022, when it surged 2048.91%.
• Tracing AGIO's Interest & Investment Income over 5 years: stood at $3.6 million in 2019, then soared by 71.84% to $6.1 million in 2020, then plunged by 94.6% to $332000.0 in 2021, then jumped by 1854.22% to $6.5 million in 2022, then grew by 27.22% to $8.3 million in 2023.
• The last three Interest & Investment Income figures came in at $8.3 million (Q2 2023), $8.1 million (Q1 2023), and $6.5 million (Q4 2022), per Business Quant data.